November 5, 2026

Corporate Name: AGC Inc.
President & CEO: Yoshinori Hirai
(Code Number: 5201; TSE Prime Market)
Contact: Kazumi Tamaki, Executive Officer, General Manager,
Corporate Communications & Investor Relations Division
(Tel: +81-3-3218-5603)

Notice Regarding Revision to Full Year Consolidated Financial Forecasts for Fiscal Year Ending December 31, 2026

AGC Inc. (the "Company") hereby announces that it has revised its full year consolidated financial forecasts for the fiscal year 2026, which were announced on February 6, 2026.

1. Revision to the consolidated financial forecasts

(1) Revision to the FY2026 consolidated financial forecasts

[January 1 through December 31, 2026]

(Unit: Millions of yen; %)

	Net sales	Operating profit	Profit before tax	Profit for the period	Profit for the period attributable to owners of the parent	Basic earnings per share (Yen)
Previous forecasts announced on February 6, 2026 (A)	2,200,000	150,000	124,000	90,000	77,000	363.12
Revised forecasts (B)	2,200,000	120,000	82,000	49,000	40,000	188.55
Change (B – A)	—	△30,000	△42,000	△41,000	△37,000	△174.57
Change (%) (B – A)/A	—	△20.0	△33.9	△45.6	△48.1	△48.1
(Reference) Actual results for FY2025	2,058,832	127,465	124,758	79,470	69,162	326.20

(2) Reasons for the revision of the consolidated financial forecasts

Operating profit is expected to be lower than the forecast due to several factors: higher manufacturing costs in North America and Europe in the Automotive segment; higher raw material and fuel prices in Essential Chemicals-SEA; and shortfalls in sales volume in Europe and Asia in the Architectural Glass segment and in the biopharmaceuticals CDMO business in the Life Science segment.

Profit before tax, profit for the period, and profit for the period attributable to owners of the parent are also expected to be lower than the previous forecasts due to the aforementioned factors and the recognition of a loss on sale of property, plant and equipment, which had not initially been anticipated, in connection with the sale of the biopharmaceuticals CDMO sites in Colorado, USA.

The dividends forecast remains unchanged despite the revision of the financial forecast.

For details, please refer to the "Presentations of Financial Results for the Nine Months ended September 30, FY2026" which disclosed today via TDnet and on our corporate website.

*The above forecasts were prepared based on the information available as of the day of this announcement. Actual results may differ from the forecast figures for various reasons.